342
Participants
Start Date
May 4, 2016
Primary Completion Date
December 13, 2017
Study Completion Date
December 26, 2017
Nemonoxacin
Solution for infusion, 500 mg (250 ml)
Nemonoxacin
Capsules, 250 mg
Tavanic
Solution for infusion, 500 mg (100 ml)
Tavanic
Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
Placebo (250 ml)
0.9% NaCl (250 ml), solution for infusion
Placebo (100 ml)
0.9% NaCl (100 ml), solution for infusion
"Regional budget healthcare institution Ivanovo regional clinical hospital", Ivanovo
City clinical hospital #1 n.a. N.I. Pirogov of Moscow Healthcare Department, Moscow
City Clinical hospital n.a. V. V. Vinogradov, Moscow
FSOE Main Military Clinical Hospital n.a. academician N.N. Burdenko of the Ministry of Defence of the Russian Federation, Moscow
SBHI Moscow City clinical hospital # 15 n.a. O.M. Filatov of Moscow Healthcare Department, Moscow
City Clinical Hospital #25, Novosibirsk
City clinical hospital #2, Novosibirsk
SBHI of Novosibirsk region City Clinical Hospital of Emergency Medical Care №2, Novosibirsk
Republic Hospital named after V.A. Baranov, Petrozavodsk
Pskov regional clinical hospital, Pskov
Baltic Medicine LLC, Saint Petersburg
City Hospital #15, Saint Petersburg
City Hospital #26, Saint Petersburg
City hospital #38 n.a. N.A. Semashko, Saint Petersburg
Mariinsky City Hospital, Saint Petersburg
Multidisciplinary City Hospital # 2, Saint Petersburg
Scientific Research Institute of Influenza of the Ministry of Healthcare of Russian Federation, Saint Petersburg
Regional clinical hospital, Saratov
Clinical hospital of emergency medical care, Smolensk
Scientific Research Institute of Antimicrobial Therapy of Smolensk State Medical University, Smolensk
Siberian State Medical University of the Ministry of Healthcare of Russian Federation, Tomsk
Ulyanovsk Regional Clinical Hospital, Ulyanovsk
Voronezh Regional Clinical Hospital #1, Voronezh
Central city hospital #7, Yekaterinburg
City clinical hospital #40, Yekaterinburg
Lead Sponsor
Collaborators (1)
OCT Clinical Trials
OTHER
R-Pharm
INDUSTRY